europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

30/07/2020
POSITION PAPER
Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

The European Association for Bioindustries (EuropaBio) and the Biotechnology Innovation Organization (BIO) welcome the opportunity to provide comments on the European Strategy for Data. Our Organisations commend the European Commission for their efforts to establish a policy framework for data with a focus on accelerating research, innovation and economic growth, particularly in the life sciences. To realize the potential of promising biotech innovations, life sciences researchers around the world require a robust and reliable global ecosystem for data; an ecosystem that allows for timely access to a wide range of data sets and where restrictions, if any, on international data flows should be transparent, limited in scope and the least trade restrictive to achieve a legitimate public policy objective.

Our Organisations are hopeful that a collaborative dialogue will help shape a policy framework for the collection, use, and international transfer of data that will enrich scientific partnerships between Europe and the U.S. and enable the next generation of data-driven advances in bioscience and life sciences innovations to be developed for the benefit of mankind. As acknowledged in the European Strategy for Data, the convergence of big data and advances in biotechnology, across the spectrum of the life sciences, is unleashing a new wave of innovations, particularly from SMEs, with the potential to profoundly improve quality of life around the world. Medicine will be revolutionized by better diagnostics and cures for diseases. Food security will be improved by enhanced quality and quantity in food and feedstuffs. Our ability to respond to climate change will improve by moving the world towards biobased and zero-waste economies.

Recognizing and respecting the values of privacy, security, safety, and ethics, our Organisations encourage the creation of a research and innovation-friendly European data policy framework that enables biotech innovation and strengthens scientific collaborations with researchers around the world. As part of an innovation-friendly data policy framework, for example, our Organisations believe that addressing certain ambiguities in the implementation of the General Data Protection Regulation (GDPR) across European Union Member States would enable data use to support cross-border scientific collaborations that benefit the public health. In addition, our Organisations recognize the potential of the European Reference Networks in the rare disease space, for instance, and how a broader policy framework which reinforces data collection, interoperability, and cross-border data sharing will accelerate breakthrough biotechnology innovations to treat patients waiting for cures.

We are encouraged that through a collaborative conversation in the context of this EU Strategy on Data we can develop policy solutions that enable data-driven innovations in the life sciences and address current challenges. Our Organisations stand ready to serve as a resource and share our collective perspectives.

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
01/02/2023

Joint Statement: The Data Act is a leap into the unknown


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies